Total Funding
8
Total FundingVenture - Series Unknown raised
Growth Score
pts
Heat Score
-13 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
1590751
Kurobe Pharmaceuticals is a developer of therapeutics for eye infections and corneal ulcers.
Barry Butler: President & Chief Executive Officer
About the Company
Kurobe, headquartered in Tampa, has licensed a product from a Japanese company to treat methicillin-resistant staphylococcus aureus (MRSA) in the eye, said Barry Butler, president and CEO.
Kurobe is one of several companies under the umbrella of Point Guard Partners LLC, established by former management executives at Sirion Holdings Inc. after
that Tampa-based biopharma firm was sold in 2010. Butler, who was CEO of Sirion, is managing partner of Point Guard.
